CA2924360C - Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer - Google Patents
Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer Download PDFInfo
- Publication number
- CA2924360C CA2924360C CA2924360A CA2924360A CA2924360C CA 2924360 C CA2924360 C CA 2924360C CA 2924360 A CA2924360 A CA 2924360A CA 2924360 A CA2924360 A CA 2924360A CA 2924360 C CA2924360 C CA 2924360C
- Authority
- CA
- Canada
- Prior art keywords
- radionuclide
- use according
- compound
- salt
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hospice & Palliative Care (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nuclear Medicine (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20130004991 EP2862857A1 (en) | 2013-10-18 | 2013-10-18 | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| EP13004991.9 | 2013-10-18 | ||
| EP14175612.2 | 2014-07-03 | ||
| EP14175612 | 2014-07-03 | ||
| PCT/EP2014/002808 WO2015055318A1 (en) | 2013-10-18 | 2014-10-17 | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2924360A1 CA2924360A1 (en) | 2015-04-23 |
| CA2924360C true CA2924360C (en) | 2022-04-26 |
Family
ID=51903864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2924360A Active 2036-10-17 CA2924360C (en) | 2013-10-18 | 2014-10-17 | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
Country Status (35)
Families Citing this family (109)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2684322T3 (es) | 2006-11-08 | 2018-10-02 | Molecular Insight Pharmaceuticals, Inc. | Heterodímeros de ácido glutámico |
| DK2187965T3 (da) | 2007-08-17 | 2020-01-20 | Purdue Research Foundation | Psma-bindingsligand-linker-konjugater og fremgangsmåder til anvendelse |
| US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
| KR102318999B1 (ko) | 2012-11-15 | 2021-10-29 | 엔도사이트, 인코포레이티드 | Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트 |
| AU2014336638C1 (en) | 2013-10-18 | 2020-09-17 | Novartis Ag | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| WO2015073678A1 (en) | 2013-11-14 | 2015-05-21 | Endocyte, Inc. | Compounds for positron emission tomography |
| US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
| US20180236109A1 (en) * | 2015-08-20 | 2018-08-23 | Universitat Zu Koln | Pain Tracking by PET-imaging (Pain-TraP) |
| PL3356385T3 (pl) | 2015-09-30 | 2021-06-28 | Deutsches Krebsforschungszentrum | Tagowane 18F inhibitory antygenu błonowego specyficznego dla gruczołu krokowego (PSMA) i ich zastosowanie jako środków do obrazowania w nowotworze gruczołu krokowego |
| US10688200B2 (en) * | 2015-12-31 | 2020-06-23 | Five Eleven Pharma Inc. | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy |
| KR20250057132A (ko) * | 2016-03-22 | 2025-04-28 | 더 존스 홉킨스 유니버시티 | 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제 |
| SG11201811482YA (en) | 2016-06-23 | 2019-01-30 | Univ Cornell | Double targeted constructs to affect tumor kill |
| US10806806B2 (en) | 2016-06-23 | 2020-10-20 | Cornell University | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies |
| US10980901B2 (en) * | 2016-12-15 | 2021-04-20 | The European Atomic Energy Community (Euratom), Represented By The European Commission | Treatment of PMSA expressing cancers |
| KR102724812B1 (ko) | 2017-04-05 | 2024-11-01 | 코넬 유니버시티 | 영상화 및 항종양 치료요법에 유용한 조정 가능한 약동학을 갖는 삼작용성 작제물 |
| JP7373998B2 (ja) | 2017-05-02 | 2023-11-06 | コーネル・ユニバーシティー | 有効性がより大きくかつ毒性がより少ない腫瘍標的指向方法及び試薬 |
| US10093741B1 (en) | 2017-05-05 | 2018-10-09 | Fusion Pharmaceuticals Inc. | IGF-1R monoclonal antibodies and uses thereof |
| WO2018204872A2 (en) | 2017-05-05 | 2018-11-08 | Fusion Pharmaceuticals Inc. | Igf-1r monoclonal antibodies and uses thereof |
| AU2018261888B2 (en) | 2017-05-05 | 2022-06-30 | Centre For Probe Development And Commercialization | Pharmacokinetic enhancements of bifunctional chelates and uses thereof |
| CA3060143A1 (en) | 2017-05-24 | 2018-11-29 | Itm Isotopen Technologien Munchen Ag | Novel psma-binding agents and uses thereof |
| WO2018233798A1 (en) | 2017-06-20 | 2018-12-27 | ITM Isotopen Technologien München AG | NOVEL PSMA BINDING AGENTS AND USE THEREOF |
| US11478558B2 (en) | 2017-05-30 | 2022-10-25 | The Johns Hopkins University | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer |
| CA3065133A1 (en) | 2017-06-09 | 2018-12-13 | Gemoab Monoclonals Gmbh | Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer, infections and autoimmune disorders |
| CN207184660U (zh) | 2017-09-15 | 2018-04-03 | 南昌欧菲光电技术有限公司 | 摄像模组 |
| CN109510921B (zh) | 2017-09-15 | 2025-01-10 | 南昌欧菲光电技术有限公司 | 摄像模组 |
| CN109510925A (zh) | 2017-09-15 | 2019-03-22 | 南昌欧菲光电技术有限公司 | 摄像模组 |
| AU2018352731B2 (en) * | 2017-10-22 | 2023-10-05 | Provincial Health Services Authority | Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer |
| EP3710068A1 (en) | 2017-11-13 | 2020-09-23 | Deutsches Krebsforschungszentrum | A double-labeled probe for molecular imaging and use thereof |
| EP3713606A1 (en) | 2017-11-21 | 2020-09-30 | Deutsches Krebsforschungszentrum | A double-labeled probe for molecular imaging and use thereof |
| DK3723815T3 (da) * | 2017-12-11 | 2022-07-11 | Univ Muenchen Tech | PSMA ligander til billeddannelse og endoradioterapi |
| DK3498308T3 (da) * | 2017-12-13 | 2025-01-02 | Sciencons AS | Kompleks, der omfatter en psma-målrettet forbindelse bundet til et bly- eller thorium-radionuklid |
| WO2019157037A1 (en) * | 2018-02-06 | 2019-08-15 | The Johns Hopkins University | Psma targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy |
| MX380340B (es) * | 2018-03-14 | 2025-03-11 | Instituto Nac De Investigaciones Nucleares | 177lu-dota-hynic-ipsma como un radiofarmaco terapeutico dirigido al antigeno prostatico especifico de membrana. |
| KR102156385B1 (ko) | 2018-03-30 | 2020-09-15 | (주)퓨쳐켐 | 전립선암 진단 및 치료를 위한 psma-표적 방사성의약품 |
| MX2020010813A (es) * | 2018-04-17 | 2021-01-08 | Endocyte Inc | Metodos de tratamiento de cancer. |
| AU2019345320B2 (en) * | 2018-09-21 | 2025-12-11 | Endocyte, Inc. | Methods of treating cancer |
| JP7429688B2 (ja) | 2018-09-21 | 2024-02-08 | エンドサイト・インコーポレイテッド | シールド剤およびそれらの使用 |
| CN121534209A (zh) * | 2018-09-28 | 2026-02-17 | 海德堡大学 | 前列腺特异性膜抗原(psma)的标记抑制剂，其作为显像剂和药剂用于治疗表达psma的癌症的用途 |
| DE102018126558A1 (de) | 2018-10-24 | 2020-04-30 | Helmholtz-Zentrum Dresden - Rossendorf E.V. | Markierungsvorläufer mit Quadratsäure-Kopplung |
| WO2020108753A1 (en) | 2018-11-28 | 2020-06-04 | ITM Isotopen Technologien München AG | Novel tumor antigen binding agents and uses thereof |
| CA3118223A1 (en) * | 2018-12-18 | 2020-06-25 | Provincial Health Services Authority | Dual mode 18f-labelled theranostic compounds and uses thereof |
| WO2020157177A1 (en) * | 2019-01-30 | 2020-08-06 | Technische Universität München | Psma binding dual mode radiotracer and therapeutic |
| CN113747927B (zh) | 2019-02-14 | 2024-10-18 | 德国癌症研究中心 | 包含淀粉酶可切割接头的前列腺特异性膜抗原(psma)配体 |
| US20220118121A1 (en) | 2019-02-14 | 2022-04-21 | Ruprecht-Karls-Universität Heidelberg | Prostate specific membrane antigen (psma) ligands with improved tissue specificity |
| US11396535B2 (en) | 2019-03-01 | 2022-07-26 | Provincial Health Services Authority | Cyclic peptide analogs of melanocortin and amanitin and methods of making such |
| PL239934B1 (pl) | 2019-04-12 | 2022-01-31 | Narodowe Centrum Badan Jadrowych Osrodek Radioizotopow Polatom | Pochodne inhibitorów PSMA do znakowania ⁹⁹ᵐTc poprzez HYNIC, zestaw radiofarmaceutyczny, preparat radiofarmaceutyczny oraz ich zastosowanie w diagnostyce raka prostaty |
| CA3136979A1 (en) * | 2019-04-17 | 2020-10-22 | Provincial Health Services Authority | Radiolabelled compounds for diagnosis or treatment of prostate-spe cific membrane antigen-expressing cancer |
| MX2021013055A (es) * | 2019-04-26 | 2021-12-10 | Five Eleven Pharma Inc | Inhibidores de antigenos de membrana especificos de prostata (psma) como agentes diagnosticos y terapeuticos con radionuclidos. |
| EP3972627A4 (en) * | 2019-05-20 | 2023-06-21 | Endocyte, Inc. | Methods for preparing psma conjugates |
| WO2020252598A1 (en) | 2019-06-21 | 2020-12-24 | Provincial Health Services Authority | Radiolabeled compounds targeting the prostate-specific membrane antigen |
| KR20220044496A (ko) * | 2019-07-02 | 2022-04-08 | 어드밴스드 액셀러레이터 어플리케이션즈 (이태리) 에스알엘 | 전립선 특이적 막 항원(psma) 리간드 및 이의 용도 |
| AR119479A1 (es) | 2019-07-25 | 2021-12-22 | Bayer As | Radiofármacos dirigidos para diagnóstico y tratamiento de cáncer |
| KR102269315B1 (ko) | 2019-10-24 | 2021-06-24 | 서울대학교산학협력단 | 전립선 암의 영상 또는 치료를 위한 동위원소 표지 화합물 |
| DE102019135564B4 (de) * | 2019-12-20 | 2022-05-19 | Johannes-Gutenberg-Universität Mainz | Verbindung für Smart-Drug-Delivery und pharmazeutisches Kit für duale nuklearmedizinisch-cytotoxische Theranostik |
| CN115380117A (zh) * | 2020-02-18 | 2022-11-22 | 恩多塞特公司 | 治疗表达psma的癌症的方法 |
| CN113350531A (zh) * | 2020-03-02 | 2021-09-07 | 上海核力星医药科技有限公司 | 前列腺特异性膜抗原结合配体偶联物及其应用 |
| WO2021202376A1 (en) | 2020-03-30 | 2021-10-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method for blocking uptake of prostate-specific membrane antigen (psma)-targeted radionuclides by exocrine organs |
| JP7894086B2 (ja) * | 2020-05-06 | 2026-07-23 | コーネル ユニヴァーシティー | 銅含有セラグノスティック化合物及びその使用の方法 |
| EP3919082A1 (en) * | 2020-06-04 | 2021-12-08 | Rigshospitalet | Psma targeting urea-based ligands for prostate cancer radiotherapy and imaging |
| JP2023539990A (ja) | 2020-07-13 | 2023-09-21 | ポイント バイオファーマ インコーポレイテッド | 放射性薬剤および方法 |
| US11129912B1 (en) | 2020-07-13 | 2021-09-28 | POINT Biopharma Inc. | Radiopharmaceutical and methods |
| CN112062695B (zh) * | 2020-08-14 | 2021-04-06 | 北京大学第一医院 | 一种前列腺特异性膜抗原靶向抑制剂及应用和探针 |
| US20230321285A1 (en) | 2020-08-31 | 2023-10-12 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| WO2022043558A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| WO2022082312A1 (en) | 2020-10-21 | 2022-04-28 | Provincial Health Services Authority | Novel cxcr4-targeting compounds |
| CN112321673B (zh) * | 2020-11-04 | 2022-09-20 | 北京市肿瘤防治研究所 | 一种前列腺特异性膜抗原靶向抑制剂及应用和探针 |
| WO2022096103A1 (en) | 2020-11-05 | 2022-05-12 | ITM Isotopen Technologien München AG | Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer |
| WO2022106629A1 (en) | 2020-11-19 | 2022-05-27 | Novartis Ag | Synthesis of prostate specific membrane antigen (psma) ligands |
| ES3053944T3 (en) * | 2020-11-19 | 2026-01-28 | Novartis Ag | Synthesis of prostate specific membrane antigen (psma) ligands |
| WO2022111800A1 (en) | 2020-11-25 | 2022-06-02 | Itm Solucin Gmbh | Stable formulations for radionuclide complexes |
| CN114685599A (zh) * | 2020-12-30 | 2022-07-01 | 南京江原安迪科正电子研究发展有限公司 | 一种psma靶向抑制剂及放射性核素标记的psma靶向抑制剂、制备方法和用途 |
| EP4023250A1 (en) * | 2021-01-04 | 2022-07-06 | Technische Universität München | Dual mode radiotracer and -therapeutics |
| DE102021101216A1 (de) | 2021-01-21 | 2022-07-21 | Johannes Gutenberg-Universität Mainz, Körperschaft des öffentlichen Rechts | Markierungsvorläufer und Radiotracer zur nuklearmedizinischen Diagnose und Therapie von Prostatakrebs induzierten Knochenmetastasen |
| CN116745323A (zh) | 2021-01-22 | 2023-09-12 | 拜耳股份有限公司 | Lrrc15抗体及其缀合物 |
| CN112898270B (zh) * | 2021-01-22 | 2023-03-21 | 周彤 | 一种诊疗一体的psma抑制剂、化合物及其制备方法与用途 |
| CN112851637B (zh) * | 2021-01-22 | 2022-11-18 | 北京瑞达福明科技有限公司 | 一种psma抑制剂、化合物及其制备方法与用途 |
| WO2022167681A1 (en) | 2021-02-08 | 2022-08-11 | Stichting Radboud Universitair Medisch Centrum | Psma-targeting ligands for multimodal applications |
| CA3212963A1 (en) * | 2021-04-23 | 2022-10-27 | Reinier HERNANDEZ | Psma-targeting ligands with optimal properties for imaging and therapy |
| EP4341296A4 (en) * | 2021-05-21 | 2025-07-30 | Northstar Medical Tech Llc | RADIOPHARMACEUTICAL PRODUCT TARGETING THE UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR |
| CN113372285B (zh) * | 2021-05-28 | 2024-06-18 | 西南医科大学附属医院 | 前列腺特异性膜抗原抑制剂、其放射性核素标记物及制法和应用 |
| DE102021114711B4 (de) | 2021-06-08 | 2023-11-02 | Medianezia GmbH | Trislinker-konjugierte dimere Markierungsvorläufer und daraus abgeleitete Radiotracer |
| EP4378948A4 (en) | 2021-07-30 | 2026-05-20 | Univ Osaka | RADIOMARKED COMPOUND AND ITS USE |
| KR20240055014A (ko) * | 2021-09-01 | 2024-04-26 | 티엔진 헨그루이 메디슨 컴퍼니 리미티드 | 전립선-특이적 막 항원 억제제 및 이의 약학적 용도 |
| JP2024532521A (ja) | 2021-09-03 | 2024-09-05 | 晶核生物医藥科技（南京）有限公司 | ペプチド－尿素誘導体、それを含む医薬組成物、及びそれらの使用 |
| CN115806529A (zh) * | 2021-09-15 | 2023-03-17 | 威智医药有限公司 | Psma结合剂及其用途 |
| CN114014843B (zh) * | 2021-11-17 | 2022-09-20 | 北京大学第一医院 | 一种psma靶向核素/荧光双模态配体和分子探针与应用 |
| US20250108139A1 (en) * | 2022-01-30 | 2025-04-03 | Bivision Pharmaceuticals, Inc | Peptide urea derivative, pharmaceutical composition containing peptide urea derivative, and application of peptide urea derivative |
| WO2023208928A1 (en) | 2022-04-26 | 2023-11-02 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Dosage of psma-ligands for fluorescence based detection of cancerous tissue |
| WO2023222681A1 (en) | 2022-05-17 | 2023-11-23 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Prostate specific membrane antigen (psma) ligands with improved renal clearance |
| KR20250016195A (ko) | 2022-05-17 | 2025-02-03 | 도이체스크레브스포르슝스젠트룸스티프퉁데스외펜트리헨레크츠 | 전립선-특이적 막 항원(psma) 리간드 |
| WO2023222679A1 (en) | 2022-05-17 | 2023-11-23 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Prostate specific membrane antigen (psma) ligands |
| CN119156234A (zh) | 2022-05-17 | 2024-12-17 | 德国癌症研究中心公共法律基金会 | 前列腺特异性膜抗原（psma）配体 |
| CN114874122A (zh) * | 2022-05-31 | 2022-08-09 | 南京航空航天大学 | 一种新的小分子抑制剂及其制备方法和应用 |
| EP4536278A4 (en) | 2022-06-07 | 2026-08-12 | Actinium Pharmaceuticals Inc | CHELETARIANS AND BIFUNCTIONAL CONJUGATES |
| AU2023283882A1 (en) | 2022-06-10 | 2025-01-30 | Peking University | Trifunctional compound and use thereof |
| IL319722A (en) | 2022-09-23 | 2025-05-01 | Nuclidium Ag | High purity radionuclides and their diagnostic and medical uses |
| TW202426433A (zh) | 2022-09-23 | 2024-07-01 | 瑞士商紐利迪姆股份公司 | 成纖維細胞活化蛋白（ｆａｐ）抑制劑、ｆａｐ結合物及其診斷與治療用途 |
| IL321958A (en) | 2023-01-10 | 2025-09-01 | Sun Pharma Advanced Res Co Ltd | Ligand-drug conjugates |
| US12539339B2 (en) * | 2023-03-24 | 2026-02-03 | Jubilant Draximage Inc. | Radiopharmaceutical conjugate compound for diagnosis and/or therapeutic uses thereof |
| EP4746926A2 (en) | 2023-07-21 | 2026-05-27 | Novartis AG | Psma-targeting radioligand treatment regimen |
| US20250213705A1 (en) | 2023-08-23 | 2025-07-03 | Bright Peak Therapeutics Ag | Psma targeting ligands and methods of use |
| WO2025071977A1 (en) * | 2023-09-28 | 2025-04-03 | The Johns Hopkins University | Pet/ct atlas for segmentation |
| WO2025088147A1 (en) | 2023-10-27 | 2025-05-01 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Theranostic psma-targeting ligands for the diagnosis and treatment of psma-expressing cancers and their solid phase synthesis |
| KR20250062978A (ko) * | 2023-10-31 | 2025-05-08 | 서울대학교병원 | 신규한 전립선 특이적 막 항원 리간드 및 이의 용도 |
| WO2025128807A1 (en) | 2023-12-13 | 2025-06-19 | Amgen Inc. | Radiolabeled compounds for the detection of steap1 |
| WO2025218879A1 (en) | 2024-04-15 | 2025-10-23 | Itm Technologies Munich Se | Stable formulations comprising 225-actinium labeled complexes and methods for preparing the same |
| WO2026088112A1 (en) | 2024-10-23 | 2026-04-30 | Novartis Ag | Combination therapies with ar-degrading agents and psma-targeting radioligands |
| EP4763231A1 (en) | 2024-12-20 | 2026-06-24 | ITM Isotope Technologies Munich SE | Para-aminohippuric acid as a stabilizer in radiopharmaceutical compositions |
| WO2026159621A1 (en) | 2025-01-23 | 2026-07-30 | Novartis Ag | Treatment regimen using psma-binding radioligands in combination with androgen receptor pathway inhibitors |
Family Cites Families (344)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4713249A (en) | 1981-11-12 | 1987-12-15 | Schroeder Ulf | Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof |
| EP0116208B1 (en) | 1982-12-07 | 1988-03-30 | Kyowa Hakko Kogyo Co., Ltd. | Mitomycin analogues |
| JPS60255789A (ja) | 1984-06-01 | 1985-12-17 | Kyowa Hakko Kogyo Co Ltd | マイトマイシン誘導体，その製造法および抗腫瘍剤 |
| US5266333A (en) | 1985-03-06 | 1993-11-30 | American Cyanamid Company | Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone |
| US5103018A (en) | 1986-08-26 | 1992-04-07 | Kyowa Hakko Kogyo Kabushiki Kaisha | Mitomycin derivatives |
| USH806H (en) | 1987-07-16 | 1990-08-07 | Fmc Corporation | Herbicidal clomazone compositions and methods of use tolerant to corn and other crops |
| EP0457875A4 (en) | 1989-11-13 | 1993-03-03 | Xoma Corporation | Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen |
| US5627165A (en) | 1990-06-13 | 1997-05-06 | Drug Innovation & Design, Inc. | Phosphorous prodrugs and therapeutic delivery systems using same |
| AU653565B2 (en) | 1990-12-21 | 1994-10-06 | Nikken Corporation | Raw sewage disposal apparatus and prefab for accomodating the same |
| US6342491B1 (en) | 1991-05-21 | 2002-01-29 | American Home Products Corporation | Method of treating estrogen receptor positive carcinoma with 17 α-dihydroequilin |
| US6291196B1 (en) | 1992-01-31 | 2001-09-18 | Research Corporation Technologies, Inc. | Melanoma and prostate cancer specific antibodies for immunodetection and immunotherapy |
| US7070782B1 (en) | 1992-11-05 | 2006-07-04 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
| US5674977A (en) | 1993-02-05 | 1997-10-07 | The Ontario Cancer Institute | Branched synthetic peptide conjugate |
| GB9314623D0 (en) | 1993-07-14 | 1993-08-25 | Nordion Int Inc | Localization and therapy with agents directed against prostate specific antigen in breast cancer |
| US6569432B1 (en) | 1995-02-24 | 2003-05-27 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen and uses thereof |
| JP3538221B2 (ja) | 1993-11-19 | 2004-06-14 | 富士写真フイルム株式会社 | 定着濃厚液およびそれを用いたハロゲン化銀写真感光材料の処理方法 |
| US5417982A (en) | 1994-02-17 | 1995-05-23 | Modi; Pankaj | Controlled release of drugs or hormones in biodegradable polymer microspheres |
| US5866679A (en) | 1994-06-28 | 1999-02-02 | Merck & Co., Inc. | Peptides |
| GB9417873D0 (en) * | 1994-09-06 | 1994-10-26 | Sandoz Ltd | Organic compounds |
| US6946133B1 (en) | 1996-03-20 | 2005-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | Prostate specific antigen oligo-epitope peptide |
| KR20060025233A (ko) | 1996-04-01 | 2006-03-20 | 에픽스 메디칼, 인코포레이티드 | 생체활성화 진단용 영상 콘트라스트 제제 |
| JP2000508171A (ja) | 1996-04-05 | 2000-07-04 | ザ・ジョンズ・ホプキンス・ユニバーシティ・スクール・オブ・メディシン | 希少細胞の富化方法 |
| US5795877A (en) | 1996-12-31 | 1998-08-18 | Guilford Pharmaceuticals Inc. | Inhibitors of NAALADase enzyme activity |
| US5902817A (en) | 1997-04-09 | 1999-05-11 | Guilford Pharmaceuticals Inc. | Certain sulfoxide and sulfone derivatives |
| US5672592A (en) | 1996-06-17 | 1997-09-30 | Guilford Pharmaceuticals Inc. | Certain phosphonomethyl-pentanedioic acid derivatives thereof |
| US6054444A (en) | 1997-04-24 | 2000-04-25 | Guilford Pharmaceuticals Inc. | Phosphonic acid derivatives |
| US5863536A (en) | 1996-12-31 | 1999-01-26 | Guilford Pharmaceuticals Inc. | Phosphoramidate derivatives |
| US5998362A (en) | 1996-09-12 | 1999-12-07 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
| US6368598B1 (en) | 1996-09-16 | 2002-04-09 | Jcrt Radiation Oncology Support Services, Inc. | Drug complex for treatment of metastatic prostate cancer |
| US5962521A (en) | 1997-04-04 | 1999-10-05 | Guilford Pharmaceuticals Inc. | Hydroxamic acid derivatives |
| US6177404B1 (en) | 1996-10-15 | 2001-01-23 | Merck & Co., Inc. | Conjugates useful in the treatment of benign prostatic hyperplasia |
| US5948750A (en) | 1996-10-30 | 1999-09-07 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
| US6548260B1 (en) | 1997-01-21 | 2003-04-15 | Bayer Corporation | Detection of PSA-α2-macroglobulin complex in a biological fluid |
| AU7019498A (en) | 1997-04-10 | 1998-10-30 | Diagnocure Inc. | Pca3, pca3 genes, and methods of use |
| WO1998052966A1 (en) | 1997-05-19 | 1998-11-26 | The Johns Hopkins University School Of Medecine | Tissue specific prodrug |
| US6504014B1 (en) | 1997-05-19 | 2003-01-07 | The John Hopkins University | Tissue specific prodrug |
| US6127333A (en) | 1997-07-10 | 2000-10-03 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
| US6391305B1 (en) | 1997-09-10 | 2002-05-21 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
| US20020115596A1 (en) | 1997-10-27 | 2002-08-22 | Merk & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
| ZA9810974B (en) | 1997-12-02 | 1999-06-03 | Merck & Co Inc | Conjugates useful in the treatment of prostate cancer |
| US20040081659A1 (en) | 1997-12-02 | 2004-04-29 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
| EP1036093A1 (en) | 1997-12-02 | 2000-09-20 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
| AU2896399A (en) | 1998-03-03 | 1999-09-20 | Exact Sciences Corporation | Purification and detection processes using reversible affinity electrophoresis |
| US20020103136A1 (en) | 1998-03-05 | 2002-08-01 | Dong-Mei Feng | Conjugates useful in the treatment of prostate cancer |
| US6232287B1 (en) | 1998-03-13 | 2001-05-15 | The Burnham Institute | Molecules that home to various selected organs or tissues |
| US6093382A (en) | 1998-05-16 | 2000-07-25 | Bracco Research Usa Inc. | Metal complexes derivatized with folate for use in diagnostic and therapeutic applications |
| FR2778820B1 (fr) | 1998-05-20 | 2000-07-28 | Rhone Poulenc Agrochimie | Melanges herbicides a base d'aclonifen et de clomazone |
| US6833438B1 (en) | 1999-06-01 | 2004-12-21 | Agensys, Inc. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
| DE69941187D1 (de) | 1998-06-01 | 2009-09-10 | Agensys Inc | Serpentintransmembranantigene exprimiert in menschlichem krebs und deren verwendungen |
| US6518033B1 (en) | 1998-08-05 | 2003-02-11 | The Research Foundation Of State University Of New York | Method of detecting the presence of CD155 for diagnosis of cancer and to determine treatment |
| US20070020327A1 (en) | 1998-11-10 | 2007-01-25 | John Fikes | Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions |
| US6174858B1 (en) | 1998-11-17 | 2001-01-16 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
| US6602274B1 (en) | 1999-01-15 | 2003-08-05 | Light Sciences Corporation | Targeted transcutaneous cancer therapy |
| US20030207808A1 (en) | 1999-02-18 | 2003-11-06 | Kinneret Savitzky | Novel nucleic acid and amino acid sequences |
| AU4063600A (en) | 1999-04-05 | 2000-10-23 | Merck & Co., Inc. | A method of treating cancer |
| JP5095050B2 (ja) | 1999-04-28 | 2012-12-12 | ジョージタウン ユニバーシティー | 代謝調節型グルタミン酸受容体のリガンド、及び、ＮＡＡＬＡＤａｓｅの阻害剤 |
| US6528499B1 (en) | 2000-04-27 | 2003-03-04 | Georgetown University | Ligands for metabotropic glutamate receptors and inhibitors of NAALADase |
| AUPQ014799A0 (en) | 1999-05-04 | 1999-05-27 | Access Pharmaceuticals Australia Pty Limited | Amplification of folate-mediated targeting to tumor cells using polymers |
| US7166573B1 (en) | 1999-05-28 | 2007-01-23 | Ludwig Institute For Cancer Research | Breast, gastric and prostate cancer associated antigens and uses therefor |
| US20040146516A1 (en) | 1999-06-17 | 2004-07-29 | Utah Ventures Ii L.P. | Lumen-exposed molecules and methods for targeted delivery |
| KR20020026530A (ko) | 1999-07-13 | 2002-04-10 | 추후제출 | Ｔ-세포 수용체 γ알터네이트 리딩 프레임단백질(ＴＡＲＰ) 및 그 용도 |
| US7060284B1 (en) | 1999-08-03 | 2006-06-13 | The Ohio State University | Polypeptides and polynucleotides for enhancing immune reactivity to HER-2 protein |
| US7361338B2 (en) | 1999-10-05 | 2008-04-22 | Agensys, Inc. | Methods to inhibit growth of prostate cancer cells |
| US6692724B1 (en) | 1999-10-25 | 2004-02-17 | Board Of Regents, The University Of Texas System | Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging |
| EP1228089A2 (en) | 1999-10-27 | 2002-08-07 | Merck & Co., Inc. | Salt form of a conjugate useful in the treatment of prostate cancer |
| US6428785B1 (en) | 1999-10-28 | 2002-08-06 | Immunolytics Inc. | Method and composition for treating prostate cancer |
| US6511676B1 (en) | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
| CA2391534A1 (en) | 1999-11-15 | 2001-05-25 | Drug Innovation & Design, Inc. | Selective cellular targeting: multifunctional delivery vehicles |
| DZ3332A1 (fr) | 2000-03-31 | 2001-10-11 | Purdue Research Foundation | Methode de traitement a l'aide de conjugues ligand-immunogene |
| US20030072794A1 (en) | 2000-06-09 | 2003-04-17 | Teni Boulikas | Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes |
| AU2002224401B2 (en) | 2000-10-16 | 2007-12-06 | Gilead Sciences, Inc. | Nucleic acid ligands to the prostate specific membrane antigen |
| US20020132983A1 (en) | 2000-11-30 | 2002-09-19 | Junghans Richard P. | Antibodies as chimeric effector cell receptors against tumor antigens |
| US7468354B2 (en) | 2000-12-01 | 2008-12-23 | Genspera, Inc. | Tissue specific prodrugs |
| JP2004536034A (ja) | 2001-01-08 | 2004-12-02 | ネオルクス コーポレイション | 治療的および診断的化合物、組成物および方法 |
| CA2436408A1 (en) | 2001-02-07 | 2002-12-12 | Beth Israel Deaconess Medical Center | Modified psma ligands and uses related thereto |
| US7767202B2 (en) | 2001-03-16 | 2010-08-03 | The Johns Hopkins University | Modulation of systemic immune responses by transplantation of hematopoietic stem cells transduced with genes encoding antigens and antigen presenting cell regulatory molecules |
| CA2441386C (en) | 2001-03-21 | 2010-12-21 | L. Molteni E C. Dei Fratelli Alitti Societa Di Esercizio S.P.A. | Metal substituted non centrosymmetrical phthalocyanine analogues, their preparation and use in photodynamic therapy and in vivo diagnostic |
| WO2002078683A1 (en) | 2001-03-29 | 2002-10-10 | Synergy Pharmaceuticals, Inc. | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
| EP1389209B1 (en) | 2001-04-24 | 2009-04-08 | Purdue Research Foundation | Folate mimetics and folate-receptor binding conjugates thereof |
| IL158532A0 (en) | 2001-05-02 | 2004-05-12 | Purdue Research Foundation | Treatment and diagnosis of macrophage mediated disease |
| US20040092890A1 (en) | 2001-05-10 | 2004-05-13 | Ash Stephen R. | Catheter lock solution including a photo-oxidant |
| US7109165B2 (en) | 2001-05-18 | 2006-09-19 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| US7514078B2 (en) | 2001-06-01 | 2009-04-07 | Cornell Research Foundation, Inc. | Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies |
| US7666414B2 (en) | 2001-06-01 | 2010-02-23 | Cornell Research Foundation, Inc. | Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen |
| CA2447695C (en) | 2001-06-01 | 2015-02-24 | Cornell Research Foundation, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
| US20040018203A1 (en) | 2001-06-08 | 2004-01-29 | Ira Pastan | Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates |
| DE60232244D1 (de) | 2001-06-21 | 2009-06-18 | Glycomimetics Inc | Nachweis und behandlung von prostatakrebs |
| US20030031677A1 (en) | 2001-06-25 | 2003-02-13 | Drug Innovation & Design, Incorporated | Exponential pattern recognition based cellular targeting, compositions, methods and anticancer applications |
| WO2003004469A1 (en) | 2001-07-02 | 2003-01-16 | Dabur Research Foundation | Anticancer activity of imino acid conjugates of methylglyoxal |
| WO2003003978A2 (en) | 2001-07-02 | 2003-01-16 | Dabur Research Foundation | An oral formulation of methylglyoxal and its imino acid conjugates for human use |
| US7893223B2 (en) | 2001-07-17 | 2011-02-22 | Bracco Imaging S.P.A. | Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy |
| EP2518142B1 (en) | 2001-08-24 | 2015-07-15 | UVic Industry Partnerships Inc. | Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer |
| US20030049203A1 (en) | 2001-08-31 | 2003-03-13 | Elmaleh David R. | Targeted nucleic acid constructs and uses related thereto |
| IL159422A0 (en) | 2001-09-20 | 2004-06-01 | Cornell Res Foundation Inc | Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen |
| US20030232760A1 (en) | 2001-09-21 | 2003-12-18 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
| DE60234782D1 (de) | 2001-09-28 | 2010-01-28 | Purdue Research Foundation | Behandlungsverfahren mit liganden-immunogenkonjugaten |
| US20030215456A1 (en) | 2001-10-02 | 2003-11-20 | Sui-Long Yao | Method of treating cancer |
| US20030133927A1 (en) | 2001-10-10 | 2003-07-17 | Defeo-Jones Deborah | Conjugates useful in the treatment of prostate cancer |
| US20040058857A1 (en) | 2001-11-29 | 2004-03-25 | Siu-Long Yao | Method of treating cancer |
| US20070031438A1 (en) | 2001-12-10 | 2007-02-08 | Junghans Richard P | Antibodies as chimeric effector cell receptors against tumor antigens |
| US20050069889A1 (en) | 2001-12-21 | 2005-03-31 | Naoki Nihei | Novel metastasis suppressor gene on human chromosome 8 |
| DE60329274D1 (de) | 2002-01-10 | 2009-10-29 | Univ Johns Hopkins | Kontrastmittel und verfahren zum imaging von naaldase oder psma |
| JP2006502964A (ja) | 2002-02-06 | 2006-01-26 | ジョンズ ホプキンス ユニバーシティ スクール オブ メディシン | 特定の器官または組織に対する全身性免疫応答の標的化のための方法および組成物 |
| US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| US8491896B2 (en) | 2002-06-14 | 2013-07-23 | Immunomedics, Inc. | Anti-pancreatic cancer antibodies |
| WO2003074450A2 (en) | 2002-02-28 | 2003-09-12 | The University Of Tennessee Research Corporation | Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy |
| US9745380B2 (en) | 2002-03-01 | 2017-08-29 | Immunomedics, Inc. | RS7 antibodies |
| US9770517B2 (en) | 2002-03-01 | 2017-09-26 | Immunomedics, Inc. | Anti-Trop-2 antibody-drug conjugates and uses thereof |
| CA2478047C (en) | 2002-03-01 | 2014-01-21 | Immunomedics, Inc. | Rs7 antibodies |
| US20170281791A1 (en) | 2002-03-01 | 2017-10-05 | Immunomedics, Inc. | Anti-trop-2 antibody-drug conjugates and uses thereof |
| CN1650033A (zh) | 2002-03-07 | 2005-08-03 | 约翰霍普金斯大学医学院 | 针对与癌症相关的表观遗传学沉默基因的基因组筛选 |
| US7534580B2 (en) | 2002-05-01 | 2009-05-19 | Ambrilia Biopharma Inc. | PSP94 diagnostic reagents and assays |
| ES2438008T3 (es) | 2002-05-06 | 2014-01-15 | Endocyte, Inc. | Agentes de formación de imágenes dirigidos a vitaminas |
| KR20040106547A (ko) | 2002-05-15 | 2004-12-17 | 엔도사이트, 인코포레이티드 | 비타민-마이토마이신 공액체 |
| ES2524767T3 (es) | 2002-06-14 | 2014-12-12 | Immunomedics, Inc. | Anticuerpo monoclonal humanizado HPAM4 |
| US7767803B2 (en) | 2002-06-18 | 2010-08-03 | Archemix Corp. | Stabilized aptamers to PSMA and their use as prostate cancer therapeutics |
| ES2369542T3 (es) | 2002-07-31 | 2011-12-01 | Seattle Genetics, Inc. | Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa. |
| AR040956A1 (es) | 2002-07-31 | 2005-04-27 | Schering Ag | Nuevos conjugados de efectores, procedimientos para su preparacion y su uso farmaceutico |
| US7749968B2 (en) | 2002-08-05 | 2010-07-06 | The Johns Hopkins University | Peptides for targeting the prostate specific membrane antigen |
| WO2004015086A2 (en) | 2002-08-08 | 2004-02-19 | Johns Hopkins University | Enhancement of adenoviral oncolytic activity in prostate cells by modification of the e1a gene product |
| US8487128B2 (en) | 2002-11-26 | 2013-07-16 | Chs Pharma, Inc. | Protection of normal cells |
| CA2508831C (en) | 2002-12-13 | 2012-05-01 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
| US8420086B2 (en) | 2002-12-13 | 2013-04-16 | Immunomedics, Inc. | Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases |
| WO2004058158A2 (en) | 2002-12-20 | 2004-07-15 | The Johns Hopkins University | Treatment of metastatic cancer with the b-subunit of shiga toxin |
| US7166691B2 (en) | 2002-12-20 | 2007-01-23 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Saposin C and receptors as targets for treatment of benign and malignant disorders |
| US7226577B2 (en) | 2003-01-13 | 2007-06-05 | Bracco Imaging, S. P. A. | Gastrin releasing peptide compounds |
| US20080008649A1 (en) * | 2003-01-13 | 2008-01-10 | Bracco Imaging S.P.A. | Gastrin Releasing Peptide Compounds |
| US7601332B2 (en) | 2003-01-27 | 2009-10-13 | Endocyte, Inc. | Vitamin receptor binding drug delivery conjugates |
| CA2514419A1 (en) | 2003-01-28 | 2004-08-12 | Proscan Rx Pharma Inc. | Prostate cancer diagnosis and treatment |
| EP1444990A1 (en) | 2003-02-07 | 2004-08-11 | Amersham plc | Improved Radiometal Complex Compositions |
| US7189723B2 (en) | 2003-02-10 | 2007-03-13 | Cgi Pharmaceuticals, Inc. | Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity |
| EP1603392A2 (en) | 2003-03-07 | 2005-12-14 | The University Of Toledo | Paclitaxel hybrid derivatives |
| US7638122B2 (en) | 2003-03-07 | 2009-12-29 | University Of South Florida | Stat3 antagonists and their use as vaccines against cancer |
| US20070179100A1 (en) | 2003-04-09 | 2007-08-02 | Muthiah Manoharan | Protected monomers |
| EP2669377A3 (en) | 2003-04-17 | 2015-10-14 | Alnylam Pharmaceuticals Inc. | Modified iRNA agents |
| EP1641742A4 (en) | 2003-05-01 | 2006-11-29 | Nst Neurosurvival Technologies | COMPOUNDS BINDING SELECTIVELY TO MEMBRANES OF APOPTOTIC CELLS |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| JP4937751B2 (ja) | 2003-06-13 | 2012-05-23 | イミューノメディクス、インコーポレイテッド | Ｄ−アミノ酸ペプチド |
| US7232805B2 (en) | 2003-09-10 | 2007-06-19 | Inflabloc Pharmaceuticals, Inc. | Cobalamin conjugates for anti-tumor therapy |
| US20050255042A1 (en) | 2003-11-24 | 2005-11-17 | The Regents Of The University Of California Office Of Technology Transfer, University Of California | On-demand cleavable linkers for radioconjugates for cancer imaging and therapy |
| FR2864546A1 (fr) | 2003-12-24 | 2005-07-01 | Assist Publ Hopitaux De Paris | Methode d'identification et de preparation de lymphocytes t regulateurs/suppresseurs, compositions et utilisations |
| JP4762156B2 (ja) | 2004-01-12 | 2011-08-31 | アプライド モレキュラー エボリューション，インコーポレイテッド | Ｆｃ領域変異体 |
| US8586932B2 (en) | 2004-11-09 | 2013-11-19 | Spectrum Dynamics Llc | System and method for radioactive emission measurement |
| DE102004004787A1 (de) | 2004-01-30 | 2005-08-18 | Schering Ag | Neue Effektor-Konjugate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung |
| CA2556752C (en) | 2004-02-23 | 2016-02-02 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| US20070254317A1 (en) | 2004-03-03 | 2007-11-01 | Biomerieux | Method for Detecting the Activatable Free Form of Psa and the Use Thereof for Diagnosing Benign Pathologies of the Prostate and Adenocarcinoma of the Prostate |
| EP1610818A4 (en) | 2004-03-03 | 2007-09-19 | Millennium Pharm Inc | MODIFIED ANTIBODIES AGAINST A PROSTATE-SPECIFIC MEMBRANE-ANTIGEN AND USE THEREOF |
| ATE403157T1 (de) | 2004-03-15 | 2008-08-15 | Hoffmann La Roche | Verwendung des bnp-art und anp-art peptiden für das festsetzen der gefahren von herzgefäss- komplikationen als folge der volumenüberlastung |
| EP1756166A4 (en) | 2004-04-19 | 2008-08-27 | Proscan Rx Pharma | DIAGNOSIS AND TREATMENT OF PROSTATE CANCER |
| WO2005111238A2 (en) | 2004-04-19 | 2005-11-24 | Archemix Corporation | Aptamer-mediated intracellular delivery of therapeutic oligonucleotides |
| BRPI0510909A2 (pt) | 2004-05-19 | 2008-12-16 | Medarex Inc | composto de ligaÇço fÁrmaco-ligante citotàxico, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula e mÉtodo para retardar ou interromper o crescimento de tumor |
| US7691962B2 (en) | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
| US20080008719A1 (en) | 2004-07-10 | 2008-01-10 | Bowdish Katherine S | Methods and compositions for the treatment of prostate cancer |
| CN101098854B (zh) | 2004-07-23 | 2012-12-05 | 恩多塞特公司 | 二价连接体及其轭合物 |
| US20060148741A1 (en) | 2004-07-26 | 2006-07-06 | Government Of The Usa, Represented By The Secretary, Department Of Health And Human Services | Metastasis suppressor gene on human chromosome 8 and its use in the diagnosis, prognosis and treatment of cancer |
| BRPI0514068B8 (pt) | 2004-08-04 | 2021-05-25 | Applied Molecular Evolution Inc | anticorpo anti-cd20, e, composição farmacêutica |
| US20060045883A1 (en) | 2004-08-26 | 2006-03-02 | Jeffrey Molldrem | Anti-cancer vaccines |
| MX2007002410A (es) | 2004-08-30 | 2007-05-07 | Neuromed Pharmaceuticals Ltd | Derivados de urea como bloqueadores de canal de calcio. |
| US8194660B2 (en) | 2004-09-09 | 2012-06-05 | Amx Llc | System, method, and computer-readable medium for dynamic device discovery for servers binding to multiple masters |
| US7713944B2 (en) | 2004-10-13 | 2010-05-11 | Isis Pharmaceuticals, Inc. | Oligomers comprising activated disulfides which bind to plasma proteins and their use for delivery to cells |
| US7638525B2 (en) | 2004-10-27 | 2009-12-29 | Janssen Pharmaceutica N.V. | Trisubstituted thiophenes as progesterone receptor modulators |
| US8000773B2 (en) | 2004-11-09 | 2011-08-16 | Spectrum Dynamics Llc | Radioimaging |
| US8606349B2 (en) | 2004-11-09 | 2013-12-10 | Biosensors International Group, Ltd. | Radioimaging using low dose isotope |
| US20060140871A1 (en) | 2004-11-30 | 2006-06-29 | Sillerud Laurel O | Magnetic resonance imaging of prostate cancer |
| EP1844351A4 (en) | 2005-01-13 | 2017-07-05 | Biosensors International Group, Ltd. | Multi-dimensional image reconstruction and analysis for expert-system diagnosis |
| US7741510B2 (en) | 2005-01-13 | 2010-06-22 | E. I. Du Pont De Nemours And Company | Rheology control agents |
| US20060155021A1 (en) | 2005-01-13 | 2006-07-13 | Lenges Christian P | Coating compositions containing rheology control agents |
| WO2006083986A2 (en) | 2005-02-01 | 2006-08-10 | Government Of The U.S.A, As Represented By The Secretary Department Of Health & Human Services | Biomarkers for tissue status |
| WO2006093991A1 (en) | 2005-03-02 | 2006-09-08 | The Cleveland Clinic Foundation | Compounds which bind psma and uses thereof |
| AU2006220621A1 (en) | 2005-03-07 | 2006-09-14 | Archemix Corp. | Stabilized aptamers to PSMA and their use as prostate cancer therapeutics |
| US8088908B2 (en) | 2005-05-10 | 2012-01-03 | City Of Hope | Humanized anti-prostate stem cell antigen monoclonal antibody |
| KR101068612B1 (ko) | 2005-05-24 | 2011-09-30 | 휴마시스 주식회사 | 유사구조 단백질 비율 측정을 이용한 진단장치 |
| CN101238145B (zh) | 2005-06-14 | 2013-04-24 | 普罗陶克斯有限公司 | 修饰的成孔蛋白在制备治疗或预防良性前列腺增生的药物中的应用 |
| AU2006262231B2 (en) | 2005-06-20 | 2013-01-24 | Psma Development Company, Llc | PSMA antibody-drug conjugates |
| JP5175723B2 (ja) | 2005-07-05 | 2013-04-03 | パーデュー・リサーチ・ファウンデーション | 単球介在性疾患を治療するための組成物の調製 |
| US20070010014A1 (en) | 2005-07-06 | 2007-01-11 | General Electric Company | Compositions and methods for enhanced delivery to target sites |
| EP1909853B1 (en) | 2005-07-19 | 2015-03-18 | Biosensors International Group, Ltd. | Imaging protocols |
| RU2470668C2 (ru) | 2005-08-19 | 2012-12-27 | Эндосайт, Инк. | Конъюгаты лиганда с несколькими лекарственными средствами |
| US20070190029A1 (en) | 2005-08-19 | 2007-08-16 | Cerus Corporation | Listeria-induced immunorecruitment and activation, and methods of use thereof |
| JP2009504783A (ja) | 2005-08-19 | 2009-02-05 | エンドサイト，インコーポレイテッド | ビンカアルカロイド、類似体および誘導体のリガンド結合体 |
| JP2009512423A (ja) | 2005-09-12 | 2009-03-26 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 抗血管新生の活性を有する組成物及びその使用 |
| US8926945B2 (en) | 2005-10-07 | 2015-01-06 | Guerbet | Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium |
| US20070134332A1 (en) | 2005-11-21 | 2007-06-14 | Medivas, Llc | Polymer particles for delivery of macromolecules and methods of use |
| CN104090095B (zh) | 2005-11-23 | 2016-06-01 | 文塔纳医疗系统公司 | 分子缀合物 |
| WO2007081751A2 (en) | 2006-01-05 | 2007-07-19 | The Johns Hopkins University | Compositions and methods for the treatment of cancer |
| US20100047170A1 (en) | 2006-01-05 | 2010-02-25 | Denmeade Samuel R | Peptide Prodrugs |
| US7635682B2 (en) | 2006-01-06 | 2009-12-22 | Genspera, Inc. | Tumor activated prodrugs |
| MX2008009970A (es) | 2006-02-01 | 2008-11-19 | Univ Johns Hopkins | Conjugados de polipeptido-acido nucleico para inmunoprofilaxis o inmunoterapia para desordenes neoplasicos o infecciosos. |
| PL1999136T3 (pl) | 2006-03-14 | 2013-03-29 | Cancer Targeted Tech Llc | Peptydomimetyczne inhibitory PSMA, związki je zawierające i sposoby ich zastosowania |
| ATE509033T1 (de) | 2006-03-20 | 2011-05-15 | Univ California | Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting |
| US20070225213A1 (en) | 2006-03-23 | 2007-09-27 | Kosak Matthew K | Nucleic acid carriers for delivery of therapeutic agents |
| US20140314864A1 (en) | 2006-03-31 | 2014-10-23 | Massachusetts Institute Of Technology | System for Targeted Delivery of Therapeutic Agents |
| WO2008105773A2 (en) | 2006-03-31 | 2008-09-04 | Massachusetts Institute Of Technology | System for targeted delivery of therapeutic agents |
| US7842280B2 (en) | 2006-09-06 | 2010-11-30 | Case Western Reserve University | Flexibly labeling peptides |
| JP2010509570A (ja) | 2006-11-03 | 2010-03-25 | パーデュー・リサーチ・ファウンデーション | エクスビボフローサイトメトリーの方法および装置 |
| ES2684322T3 (es) | 2006-11-08 | 2018-10-02 | Molecular Insight Pharmaceuticals, Inc. | Heterodímeros de ácido glutámico |
| US9387344B2 (en) | 2006-11-21 | 2016-07-12 | The Johns Hopkins University | Methods for determining absorbed dose information |
| US20100210792A1 (en) | 2006-12-05 | 2010-08-19 | David Taft | Drug delivery |
| WO2008085828A2 (en) | 2007-01-03 | 2008-07-17 | The Johns Hopkins University | Peptide modulators of angiogenesis and use thereof |
| CN101568352B (zh) | 2007-01-11 | 2013-08-21 | 免疫医学股份有限公司 | 用于蛋白质、肽和其他分子的改进的f-18标记的方法和组合物 |
| US20080214436A1 (en) | 2007-01-26 | 2008-09-04 | City Of Hope | Methods and compositions for the treatment of cancer or other diseases |
| US8586595B2 (en) | 2007-02-07 | 2013-11-19 | Purdue Research Foundation | Positron emission tomography imaging method |
| US20100104626A1 (en) | 2007-02-16 | 2010-04-29 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
| CN104127878A (zh) | 2007-03-14 | 2014-11-05 | 恩多塞特公司 | 结合配体连接的微管溶素递药缀合物 |
| EP2155231B1 (en) | 2007-04-10 | 2012-08-08 | The Johns Hopkins University | Imaging and therapy of virus-associated tumors |
| BRPI0812970A2 (pt) | 2007-06-25 | 2019-09-24 | Endocyte Inc | conjugados contendo espaçadores hidrofílicos |
| WO2009002529A2 (en) | 2007-06-26 | 2008-12-31 | The Johns Hopkins University | Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents |
| GB0723246D0 (en) | 2007-07-03 | 2008-01-09 | Barton Michelle | p53 modulator |
| CN101784564B (zh) | 2007-07-13 | 2014-07-02 | 约翰霍普金斯大学 | B7-dc变体 |
| EP2178896A1 (en) | 2007-07-31 | 2010-04-28 | The Johns Hopkins University | Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders |
| US8013991B2 (en) | 2007-08-08 | 2011-09-06 | Chemimage Corporation | Raman difference spectra based disease classification |
| DK2187965T3 (da) | 2007-08-17 | 2020-01-20 | Purdue Research Foundation | Psma-bindingsligand-linker-konjugater og fremgangsmåder til anvendelse |
| EP2185188B1 (en) | 2007-08-22 | 2014-08-06 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
| WO2009033161A1 (en) | 2007-09-07 | 2009-03-12 | The John Hopkins University | Adenosine receptor agonists and antagonists to modulate t cell responses |
| WO2009035942A1 (en) | 2007-09-13 | 2009-03-19 | Chemimage Corporation | Distinguishing between renal oncocytoma and chromophobe renal cell carcinoma using raman molecular imaging |
| ATE530169T1 (de) | 2007-09-28 | 2011-11-15 | Bind Biosciences Inc | Krebszellen-targeting mit nanopartikeln |
| EP2209374B1 (en) | 2007-10-25 | 2014-12-03 | Endocyte, Inc. | Tubulysins and processes for preparing |
| US8450290B2 (en) | 2007-11-26 | 2013-05-28 | Enzon Pharmaceuticals, Inc. | Methods for treating androgen receptor dependent disorders including cancers |
| US9422234B2 (en) | 2007-11-30 | 2016-08-23 | The Johns Hopkins University | Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer |
| US8507455B2 (en) | 2007-12-04 | 2013-08-13 | Alnylam Pharmaceuticals, Inc. | Folate conjugates |
| WO2009076434A1 (en) | 2007-12-12 | 2009-06-18 | Molecular Insight Pharmaceuticals, Inc. | Inhibitors of integrin vla-4 |
| CA2711678A1 (en) | 2008-01-09 | 2009-07-16 | Molecular Insight Pharmaceuticals, Inc. | Inhibitors of carbonic anhydrase ix |
| US8565945B2 (en) | 2008-01-17 | 2013-10-22 | Lockheed Martin Corporation | Method for managing vital train movements |
| JP2011516178A (ja) | 2008-04-04 | 2011-05-26 | モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド | 放射能標識治療物質注入システム、装置、およびそれを使用する方法 |
| ITTO20080313A1 (it) | 2008-04-22 | 2009-10-23 | Marco Colombatti | Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi |
| US8258111B2 (en) | 2008-05-08 | 2012-09-04 | The Johns Hopkins University | Compositions and methods related to miRNA modulation of neovascularization or angiogenesis |
| US8852630B2 (en) | 2008-05-13 | 2014-10-07 | Yale University | Chimeric small molecules for the recruitment of antibodies to cancer cells |
| HRP20151367T1 (hr) | 2008-05-13 | 2016-01-29 | Yale University | Kimerne male molekule za pojaäśanje odgovora protutijela na stanice raka |
| AU2009268923B2 (en) | 2008-06-16 | 2015-09-17 | Pfizer Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
| WO2010002418A2 (en) | 2008-07-01 | 2010-01-07 | The Johns Hopkins University | Quick-dissolving oral thin film for targeted delivery of therapeutic agents |
| ES2634894T3 (es) | 2008-08-01 | 2017-09-29 | The Johns Hopkins University | Agentes de unión a PSMA y usos de los mismos |
| US8685937B2 (en) | 2008-08-09 | 2014-04-01 | University Of Iowa Research Foundation | Nucleic acid aptamers |
| WO2010027641A2 (en) | 2008-08-15 | 2010-03-11 | Georgetown University | Na channels, disease, and related assays and compositions |
| EP2326350B1 (en) | 2008-09-08 | 2013-09-04 | Psma Development Company, L.L.C. | Compounds for killing psma-expressing, taxane-resistant cancer cells |
| EP2166021A1 (en) | 2008-09-16 | 2010-03-24 | Ganymed Pharmaceuticals AG | Monoclonal antibodies for treatment of cancer |
| JP5675619B2 (ja) | 2008-09-17 | 2015-02-25 | エンドサイト, インク.Endocyte, Inc. | 葉酸拮抗薬の葉酸受容体結合性コンジュゲート |
| US20110288152A1 (en) | 2008-10-17 | 2011-11-24 | Purdue Research Foundation | Psma binding ligand-linker conjugates and methods for using |
| AU2009322167B2 (en) | 2008-12-05 | 2014-11-20 | Molecular Insight Pharmaceuticals, Inc. | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof for inhibiting PSMA |
| US8211402B2 (en) | 2008-12-05 | 2012-07-03 | Molecular Insight Pharmaceuticals, Inc. | CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer |
| WO2010065899A2 (en) | 2008-12-05 | 2010-06-10 | Molecular Insight Pharmaceuticals, Inc. | Technetium-and rhenium-bis(heteroaryl)complexes and methods of use thereof |
| PL3912643T3 (pl) | 2009-02-13 | 2023-01-23 | Immunomedics Inc. | Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo |
| JP5906090B2 (ja) | 2009-02-17 | 2016-04-20 | コーネル・リサーチ・ファンデーション・インコーポレイテッドＣｏｒｎｅｌｌ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ， Ｉｎｃｏｒｐｏｒａｔｅｄ | 癌の診断のための方法およびキットならびに治療価の推定 |
| WO2010101627A2 (en) | 2009-03-02 | 2010-09-10 | Massachusetts Institute Of Technology | Methods and systems for treatment and/or diagnosis |
| US8772226B2 (en) | 2009-03-17 | 2014-07-08 | The Johns Hopkins University | Methods and compositions for the detection of cancer |
| EP4420730A3 (en) * | 2009-03-19 | 2024-11-13 | The Johns Hopkins University | Psma-targeting compounds and uses thereof |
| US10717750B2 (en) | 2009-03-19 | 2020-07-21 | The Johns Hopkins University | 68Ga-labeled NOTA-chelated PSMA-targeted imaging and therapeutic agents |
| US9757084B2 (en) | 2011-12-22 | 2017-09-12 | The Johns Hopkins University | Method and system for administering radiopharmaceutical therapy (RPT) |
| CA2769444A1 (en) | 2009-05-19 | 2010-11-25 | Aic Blab Company | Composite current collector and methods therefor |
| BR112012000209B8 (pt) | 2009-06-15 | 2021-07-27 | Molecular Insight Pharm Inc | heterodímeros de ácido glutâmico e seus processos de preparação |
| US20120128587A1 (en) | 2009-07-31 | 2012-05-24 | Endocyte, Inc. | Folate-targeted diagnostics and treatment |
| US8394922B2 (en) | 2009-08-03 | 2013-03-12 | Medarex, Inc. | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof |
| US8685891B2 (en) | 2009-08-27 | 2014-04-01 | Nuclea Biotechnologies, Inc. | Method and assay for determining FAS expression |
| CA3040276A1 (en) | 2009-12-02 | 2011-06-09 | Imaginab, Inc. | J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use |
| CN102811743B (zh) | 2009-12-11 | 2015-11-25 | 佰恩德治疗股份有限公司 | 冻干治疗颗粒的稳定制剂 |
| JP5964756B2 (ja) | 2010-02-04 | 2016-08-03 | ラジウス ヘルス，インコーポレイテッド | 選択的アンドロゲン受容体モジュレーター |
| US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
| CA2790577A1 (en) | 2010-02-25 | 2011-09-01 | Purdue Research Foundation | Psma binding ligand-linker conjugates and methods for using |
| US8685416B2 (en) | 2010-03-02 | 2014-04-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for the treatment of cancer |
| JP2010159277A (ja) | 2010-03-04 | 2010-07-22 | Sumitomo Chemical Co Ltd | 有害生物防除組成物及び有害生物の防除方法 |
| EP2371864A1 (en) | 2010-03-23 | 2011-10-05 | Ganymed Pharmaceuticals AG | Monoclonal antibodies for treatment of cancer |
| US9006415B2 (en) | 2010-04-06 | 2015-04-14 | Massachusetts Institute Of Technology | Targeted delivery of nucleic acids |
| PT2528625E (pt) | 2010-04-15 | 2013-10-17 | Spirogen Sarl | Pirrolobenzodiazepinas e conjugados das mesmas |
| HUE029293T2 (en) | 2010-05-05 | 2017-02-28 | Safety Syringes Inc | Helical-shaped coil safety device for needle |
| CN101863924B (zh) | 2010-05-17 | 2012-06-27 | 北京师范大学 | 99mTc标记肼基烟酰胺基-二氧辛酰-叶酸配合物及制备方法 |
| CN103118678A (zh) | 2010-07-16 | 2013-05-22 | 约翰斯·霍普金斯大学 | 用于癌症免疫治疗的方法和组合物 |
| US9029340B2 (en) | 2010-07-22 | 2015-05-12 | The Johns Hopkins University | Radiation sensitization agents for prostate cancer |
| US9580474B2 (en) | 2010-09-08 | 2017-02-28 | The Johns Hopkins University | Polyionic papilloma virus-like particle (VLP) vaccines |
| KR101236142B1 (ko) | 2010-09-30 | 2013-02-21 | 경북대학교 산학협력단 | 가돌리늄 착물을 함유하는 ｍｒｉ조영제 |
| US9687572B2 (en) | 2010-12-06 | 2017-06-27 | Molecular Insight Pharmaceuticals, Inc. | PSMA-targeted dendrimers |
| WO2012135592A2 (en) | 2011-03-31 | 2012-10-04 | The Johns Hopkins University | Theranostic imaging agents and methods of use |
| ES2785081T3 (es) | 2011-04-01 | 2020-10-05 | Memorial Sloan Kettering Cancer Center | Anticuerpos biespecíficos similares a receptores de células T específicos para un péptido de WT1 presentado por HLA-A2 |
| JP5964407B2 (ja) | 2011-04-21 | 2016-08-03 | オリオン コーポレーション | アンドロゲン受容体調節カルボキシアミド |
| US9180214B1 (en) | 2011-04-22 | 2015-11-10 | Stc.Unm | Gonadotropin-releasing hormone receptor-targeting peptides and their use to treat and diagnose cancer |
| WO2012154511A2 (en) | 2011-05-06 | 2012-11-15 | The Johns Hopkins University | Method and device for statistical tissue sampling using microdevices |
| US20140308363A1 (en) | 2011-05-31 | 2014-10-16 | Bind Therapeutics, Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
| PL2721039T3 (pl) * | 2011-06-15 | 2018-06-29 | Cancer Targeted Technology Llc | Chelatowane inhibitory PSMA |
| JP5843338B2 (ja) * | 2011-08-05 | 2016-01-13 | モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド | 放射標識された前立腺特異的膜抗原阻害剤 |
| US10011632B2 (en) | 2011-08-22 | 2018-07-03 | Siemens Medical Solutions Usa, Inc. | PSMA imaging agents |
| US9034318B2 (en) | 2011-08-30 | 2015-05-19 | The Regents Of The University Of Colorado, A Body Corporate | Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria |
| WO2013060793A1 (en) * | 2011-10-25 | 2013-05-02 | Technische Universität München | Bifunctional ligands for radiometals |
| WO2013070457A2 (en) | 2011-11-01 | 2013-05-16 | The Johns Hopkins University | Method and device for endoscopic abrasion |
| EP2785712B1 (en) | 2011-11-30 | 2019-05-01 | The Johns Hopkins University | Homomultivalent and heteromultivalent inhibitors of prostate specific membrane antigen (pmsa) and uses thereof |
| US9120837B2 (en) | 2012-01-06 | 2015-09-01 | Molecular Insight Pharmaceuticals | Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase IX |
| US9629918B2 (en) | 2012-02-29 | 2017-04-25 | Purdue Research Foundation | Folate receptor alpha binding ligands |
| US9498546B2 (en) | 2012-03-14 | 2016-11-22 | The Johns Hopkins University | Synthesis and application of novel imaging agents conjugated to DPA 713 analogs for imaging inflammation |
| US9556167B2 (en) | 2012-05-02 | 2017-01-31 | Yale University | TLR-agonist-conjugated antibody recruiting molecules (TLR-ARMs) |
| EP2858722B8 (en) | 2012-06-08 | 2018-02-21 | Aduro BioTech, Inc. | Compostions and methods for cancer immunotherapy |
| BR122017017921A2 (pt) | 2012-07-27 | 2019-09-10 | Aragon Pharmaceuticals, Inc. | métodos e sistema para determinar a resistência à terapia de receptor de androgênio |
| EA201590622A1 (ru) | 2012-10-16 | 2015-10-30 | Эндосайт, Инк. | Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения |
| US20140107316A1 (en) | 2012-10-16 | 2014-04-17 | Endocyte, Inc. | Drug delivery conjugates containing unnatural amino acids and methods for using |
| US20140113322A1 (en) | 2012-10-22 | 2014-04-24 | The Johns Hopkins University | Supramolecular nanobeacon imaging agents as protease sensors |
| US9180203B2 (en) | 2012-10-23 | 2015-11-10 | The Johns Hopkins University | Self-assembling drug amphiphiles and methods for synthesis and use |
| KR102318999B1 (ko) | 2012-11-15 | 2021-10-29 | 엔도사이트, 인코포레이티드 | Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트 |
| US20140154702A1 (en) | 2012-11-30 | 2014-06-05 | Endocyte, Inc. | Methods For Treating Cancer Using Combination Therapies |
| KR102002826B1 (ko) | 2012-12-04 | 2019-07-23 | 삼성전자 주식회사 | 저장 장치, 플래시 메모리 및 저장 장치의 동작 방법 |
| US9567340B2 (en) | 2012-12-21 | 2017-02-14 | Medimmune Limited | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases |
| HK1217085A1 (zh) | 2012-12-28 | 2016-12-23 | Tarveda Therapeutics, Inc | 包封在顆粒中的靶向綴合物及其製劑 |
| HUE035739T2 (en) | 2013-01-14 | 2018-05-28 | Molecular Insight Pharm Inc | Triazine-based radiopharmaceuticals and radiological imaging agents |
| EP2958596B1 (en) | 2013-02-15 | 2019-12-04 | Case Western Reserve University | Psma ligands and uses thereof |
| US10207005B2 (en) | 2013-02-15 | 2019-02-19 | Case Western Reserve University | Photodynamic therapy composition |
| US20140249315A1 (en) | 2013-03-01 | 2014-09-04 | Endocyte, Inc. | Processes for preparing tubulysins |
| US9255262B2 (en) | 2013-03-06 | 2016-02-09 | Vision Global Holdings Ltd. | Albumin-binding arginine deminase and the use thereof |
| US9567402B2 (en) | 2013-03-14 | 2017-02-14 | The Regents Of The University Of California | Internalizing human monoclonal antibodies targeting prostate and other cancer cells |
| US10434194B2 (en) | 2013-06-20 | 2019-10-08 | Case Western Reserve University | PSMA targeted nanobubbles for diagnostic and therapeutic applications |
| WO2015006555A2 (en) | 2013-07-10 | 2015-01-15 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| JP5817799B2 (ja) | 2013-10-10 | 2015-11-18 | ダイキン工業株式会社 | 空気調和機 |
| US10010624B2 (en) | 2013-10-11 | 2018-07-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| WO2015057692A1 (en) | 2013-10-14 | 2015-04-23 | The Johns Hopkins University | Prostate-specific membrane antigen-targeted photosensitizers for photodynamic therapy |
| US10406246B2 (en) | 2013-10-17 | 2019-09-10 | Deutsches Kresbsforschungszentrum | Double-labeled probe for molecular imaging and use thereof |
| EP3057620A4 (en) | 2013-10-18 | 2017-05-24 | Molecular Insight Pharmaceuticals, Inc. | Methods of using spect/ct analysis for staging cancer |
| WO2015057250A1 (en) | 2013-10-18 | 2015-04-23 | Psma Development Company, Llc | Combination therapies with psma ligand conjugates |
| AU2014336638C1 (en) * | 2013-10-18 | 2020-09-17 | Novartis Ag | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| WO2015073678A1 (en) | 2013-11-14 | 2015-05-21 | Endocyte, Inc. | Compounds for positron emission tomography |
| ITAN20130219A1 (it) | 2013-11-21 | 2015-05-22 | Gianluca Valentini | Farmaco anti-cancro, comprendente un radioisotopo del rame |
| MX2016006486A (es) | 2013-11-25 | 2016-08-05 | Oxford Biotherapeutics Ltd | Anticuerpos. |
| US9346846B1 (en) | 2013-12-02 | 2016-05-24 | Yale University | Anti-cancer compounds and methods for treating cancer |
| US10363388B2 (en) | 2013-12-18 | 2019-07-30 | Koninklijke Philips N.V. | System and method for enhancing sleep slow wave activity based on cardiac characteristics or respiratory characteristics |
| WO2015143029A1 (en) | 2014-03-18 | 2015-09-24 | The Johns Hopkins University | Psma-based molecular-genetic reporter system |
| ES2743482T3 (es) | 2014-05-06 | 2020-02-19 | Univ Johns Hopkins | Inhibidores de PSMA marcados con metal/radiometal para obtención de imágenes dirigidas a PSMA y radioterapia |
| EP2944635B1 (en) | 2014-05-15 | 2018-11-28 | Council of Scientific & Industrial Research | Pyrazole linked benzimidazole conjugates and a process for preparation thereof |
| US9814759B2 (en) | 2014-07-02 | 2017-11-14 | Cheer Global Ltd. | Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment |
| ES2908411T3 (es) | 2014-08-06 | 2022-04-29 | Univ Johns Hopkins | Profármacos del inhibidor del antígeno de membrana específico de la próstata (PSMA) |
| US10172873B2 (en) | 2014-08-06 | 2019-01-08 | The Johns Hopkins University | Methods for treating inflammatory bowel disease using prostate specific membrane antigen (PSMA) inhibitors |
| EP2993171A1 (en) | 2014-09-04 | 2016-03-09 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for the production of 18F-labeled PSMA-specific PET-tracers |
| US10112974B2 (en) | 2014-08-24 | 2018-10-30 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Method for the production of 18F-labeled active esters and their application exemplified by the preparation of a PSMA-specific PET-tracer |
| WO2016033114A1 (en) | 2014-08-25 | 2016-03-03 | The Johns Hopkins University | Methods and compositions related to prostate cancer therapeutics |
| JP2017530109A (ja) | 2014-09-08 | 2017-10-12 | モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド | 前立腺癌についてのｐｓｍａを標的とした放射性核種治療中の臓器の保護 |
| EP3209336B1 (en) | 2014-10-20 | 2019-12-11 | Deutsches Krebsforschungszentrum | 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| WO2016065142A2 (en) | 2014-10-22 | 2016-04-28 | The Johns Hopkins University | New scaffolds and multifunctional intermediates for imaging psma and cancer therapy |
| US11033637B2 (en) | 2014-11-21 | 2021-06-15 | University Of Maryland, Baltimore | Targeted structure-specific particulate delivery systems |
| KR101698654B1 (ko) | 2014-12-24 | 2017-01-20 | 포항공과대학교 산학협력단 | En2에 특이적으로 결합하는 dna 압타머 및 이의 용도 |
| US20180148480A1 (en) | 2015-01-16 | 2018-05-31 | The Johns Hopkins University | Synthetic enhancement of the t-cell armamentarium as an anti-cancer therapy |
| US10596226B2 (en) | 2015-01-16 | 2020-03-24 | The Johns Hopkins University | Albumin-proaerolysin prodrugs |
| HK1250662A1 (zh) | 2015-04-13 | 2019-01-11 | Aduro Biotech, Inc. | 用於治疗癌症的免疫原性融合蛋白 |
| WO2016168595A1 (en) | 2015-04-17 | 2016-10-20 | Barrett David Maxwell | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| US9808538B2 (en) | 2015-09-09 | 2017-11-07 | On Target Laboratories, LLC | PSMA-targeted NIR dyes and their uses |
| KR101639599B1 (ko) | 2015-11-09 | 2016-07-14 | 서울대학교산학협력단 | 펩타이드 싸이오우레아 유도체, 이를 포함하는 방사성 동위원소 표지 화합물 및 이를 유효 성분으로 함유하는 전립선암 치료 또는 진단용 약학적 조성물 |
| FR3043970B1 (fr) | 2015-11-25 | 2019-06-21 | Medtech Sa | Systeme mecanique de stabilisation au sol pour vehicules a roulettes |
| US10688200B2 (en) | 2015-12-31 | 2020-06-23 | Five Eleven Pharma Inc. | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy |
| EP3510399B1 (en) | 2016-09-09 | 2023-03-01 | On Target Laboratories, LLC | Psma-targeted nir dyes and their uses |
| SG11201909513QA (en) | 2017-04-11 | 2019-11-28 | Univ Johns Hopkins | Prodrugs of 2-pmpa for healthy tissue protection during psma-targeted cancer imaging or radiotherapy |
| DK3498308T3 (da) | 2017-12-13 | 2025-01-02 | Sciencons AS | Kompleks, der omfatter en psma-målrettet forbindelse bundet til et bly- eller thorium-radionuklid |
| WO2019165200A1 (en) | 2018-02-22 | 2019-08-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents for targeting prostate cancer |
| CN119143875A (zh) | 2018-06-21 | 2024-12-17 | 瑞泽恩制药公司 | 双特异性抗psma x抗cd28抗体及其用途 |
-
2014
- 2014-10-17 AU AU2014336638A patent/AU2014336638C1/en active Active
- 2014-10-17 LT LTEP22178736.9T patent/LT4095130T/lt unknown
- 2014-10-17 KR KR1020197003504A patent/KR102210931B1/ko active Active
- 2014-10-17 SG SG11201602249RA patent/SG11201602249RA/en unknown
- 2014-10-17 PE PE2016000519A patent/PE20160678A1/es unknown
- 2014-10-17 KR KR1020167012314A patent/KR101947053B1/ko active Active
- 2014-10-17 HU HUE22178736A patent/HUE066137T2/hu unknown
- 2014-10-17 EP EP22178736.9A patent/EP4095130B1/en active Active
- 2014-10-17 CN CN201480056250.5A patent/CN105636924B/zh active Active
- 2014-10-17 GE GEAP201414132A patent/GEP20217330B/en unknown
- 2014-10-17 MX MX2016005013A patent/MX2016005013A/es unknown
- 2014-10-17 KR KR1020217002788A patent/KR102282378B1/ko active Active
- 2014-10-17 EP EP18184296.4A patent/EP3456700A1/en not_active Withdrawn
- 2014-10-17 JP JP2016524427A patent/JP2016535013A/ja not_active Ceased
- 2014-10-17 EA EA201690495A patent/EA037778B1/ru unknown
- 2014-10-17 FI FIEP22178736.9T patent/FI4095130T3/fi active
- 2014-10-17 CN CN201810815832.7A patent/CN109053616B/zh active Active
- 2014-10-17 PH PH1/2019/502571A patent/PH12019502571A1/en unknown
- 2014-10-17 EP EP24154479.0A patent/EP4374924A3/en active Pending
- 2014-10-17 EP EP18172716.5A patent/EP3415489A1/en not_active Withdrawn
- 2014-10-17 WO PCT/EP2014/002808 patent/WO2015055318A1/en not_active Ceased
- 2014-10-17 ES ES22178736T patent/ES2977715T3/es active Active
- 2014-10-17 NZ NZ718812A patent/NZ718812A/en unknown
- 2014-10-17 RS RS20240346A patent/RS65324B1/sr unknown
- 2014-10-17 GE GEAP201415377A patent/GEP20237479B/en unknown
- 2014-10-17 TN TN2016000137A patent/TN2016000137A1/en unknown
- 2014-10-17 PE PE2021001264A patent/PE20211760A1/es unknown
- 2014-10-17 DK DK22178736.9T patent/DK4095130T3/da active
- 2014-10-17 EP EP14799340.6A patent/EP3038996B1/en not_active Withdrawn - After Issue
- 2014-10-17 GE GEAP202215377A patent/GEAP202215377A/en unknown
- 2014-10-17 GE GEAP202215719A patent/GEAP202215719A/en unknown
- 2014-10-17 GE GEAP201415719A patent/GEP20237496B/en unknown
- 2014-10-17 GE GEAP201415720A patent/GEP20237497B/en unknown
- 2014-10-17 DE DE202014011600.8U patent/DE202014011600U1/de not_active Expired - Lifetime
- 2014-10-17 EP EP18203547.7A patent/EP3495355A1/en not_active Withdrawn
- 2014-10-17 MY MYPI2016000645A patent/MY188934A/en unknown
- 2014-10-17 HR HRP20240398TT patent/HRP20240398T1/hr unknown
- 2014-10-17 SI SI201432067T patent/SI4095130T1/sl unknown
- 2014-10-17 PL PL22178736.9T patent/PL4095130T3/pl unknown
- 2014-10-17 CA CA2924360A patent/CA2924360C/en active Active
- 2014-10-17 GE GEAP202114132A patent/GEAP202114132A/en unknown
- 2014-10-17 DE DE202014011593.1U patent/DE202014011593U1/de not_active Expired - Lifetime
- 2014-10-17 MY MYPI2020002949A patent/MY194484A/en unknown
-
2016
- 2016-03-31 SA SA516370842A patent/SA516370842B1/ar unknown
- 2016-04-08 PH PH12016500656A patent/PH12016500656A1/en unknown
- 2016-04-14 IL IL245113A patent/IL245113B/en active IP Right Grant
- 2016-04-14 CL CL2016000883A patent/CL2016000883A1/es unknown
- 2016-04-18 MX MX2021008976A patent/MX2021008976A/es unknown
- 2016-04-18 MX MX2021008977A patent/MX2021008977A/es unknown
- 2016-04-18 US US15/131,118 patent/US20160228587A1/en not_active Abandoned
- 2016-05-18 ZA ZA2016/03380A patent/ZA201603380B/en unknown
-
2017
- 2017-10-17 GE GEAP202215720A patent/GEAP202215720A/en unknown
- 2017-10-31 JP JP2017210775A patent/JP6556805B2/ja active Active
-
2018
- 2018-01-18 AU AU2018200419A patent/AU2018200419B2/en active Active
- 2018-07-18 US US16/038,729 patent/US10471160B2/en active Active
- 2018-08-28 US US16/114,988 patent/US10398791B2/en active Active
- 2018-10-12 JP JP2018193272A patent/JP6901451B2/ja active Active
-
2019
- 2019-07-10 JP JP2019128294A patent/JP7036774B2/ja active Active
- 2019-07-12 US US16/510,495 patent/US20190336622A1/en not_active Abandoned
- 2019-08-26 US US16/551,198 patent/US11045564B2/en active Active
- 2019-08-28 IL IL268974A patent/IL268974B/en active IP Right Grant
- 2019-11-18 ZA ZA2019/07607A patent/ZA201907607B/en unknown
-
2020
- 2020-02-14 AU AU2020201086A patent/AU2020201086B2/en active Active
- 2020-12-03 US US17/110,558 patent/US11931430B2/en active Active
- 2020-12-08 JP JP2020203704A patent/JP7194161B2/ja active Active
-
2021
- 2021-01-07 US US17/143,280 patent/US11951190B2/en active Active
-
2022
- 2022-08-01 JP JP2022122499A patent/JP7393485B2/ja active Active
-
2023
- 2023-11-24 JP JP2023198760A patent/JP2024028742A/ja active Pending
-
2024
- 2024-02-13 US US18/440,783 patent/US20240350680A1/en active Pending
- 2024-04-05 US US18/628,570 patent/US20240382631A1/en active Pending
- 2024-06-28 FI FIC20240024C patent/FIC20240024I1/fi unknown
- 2024-06-28 LU LU00352C patent/LUC00352I2/en unknown
- 2024-07-02 FR FR24C1028C patent/FR24C1028I2/fr active Active
- 2024-07-04 LT LTPA2024522C patent/LTPA2024522I1/lt unknown
- 2024-07-05 CY CY2024023C patent/CY2024023I2/el unknown
- 2024-07-10 NL NL301281C patent/NL301281I2/nl unknown
- 2024-07-10 HU HUS2400024C patent/HUS2400024I1/hu unknown
-
2025
- 2025-09-11 US US19/326,529 patent/US20260007785A1/en active Pending
- 2025-09-11 US US19/326,445 patent/US20260007784A1/en active Pending
-
2026
- 2026-05-07 JP JP2026078032A patent/JP2026119201A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11951190B2 (en) | Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer | |
| EP2862857A1 (en) | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
| HK40110189A (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
| HK40080502A (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
| HK40080502B (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
| HK40010018A (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
| HK40006280A (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
| HK40001785A (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20160525 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD Year of fee payment: 10 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240930 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240930 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240930 |
|
| P14 | Amendment of ip right document requested |
Free format text: ST27 STATUS EVENT CODE: A-4-4-P10-P14-P133 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRECTION REQUEST FOR A GRANTED PATENT Effective date: 20241217 |
|
| R15 | Change to inventor requested |
Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R15-R108 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRECT INVENTOR REQUEST RECEIVED Effective date: 20241217 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241217 Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED Effective date: 20241217 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD Year of fee payment: 11 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250916 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250916 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260316 |